Study: Biodegradable stents beat drug-eluting counterparts; What's the best way to clean neurosurgery tools?;

@FierceMedDev: Pfizer, marketing partner pay MA fine for ad overstating EpiPen's benefits. More | Follow @FierceMedDev

@MarkHFierce: Novartis is unloading its blood transfusion Dx unit for more than $1.6B PR. Article | Follow @MarkHFierce

@MichaelGFierce: ICYMI: Chinese investors pursue groundbreaking med tech from Canada's MDI. Story | Follow @MichaelGFierce

> Biodegradable stents work better than first-generation drug-eluting stents but are no better than new drug-eluting stents made with a durable polymer, a new analysis concluded. Story (sub. req.) 

> A new U.K. study will attempt to determine the best methods for cleaning neurosurgery-related surgical instruments. Story

> Titan Spine said it has reached 18,000 implantations of its Endoskeleton interbody fusion devices. Item

> Advanced Cell Diagnostics has signed up a new CLIA-certified service provider for its RNAscope technology designed to help validate biomarkers for use in the development of targeted treatments. Item

> Price cuts on contraceptive implants set up their expanded use in the developing world. Story

Biotech News

@FierceBiotech: Shire pays a steep premium to nab ViroPharma in $4.2B deal. More | Follow @FierceBiotech

@JohnCFierce: Just a few weeks ago Zalicus ($ZLCS) did a 6 for one reverse split to get its stock price back into compliance. Oh well. | Follow @JohnCFierce

@DamianFierce: Still-blazing IPO market takes Ultragenyx from "next year" to "right now." News | Follow @DamianFierce

@EmilyMFierce: Japanese Global Health Innovative Technology Fund awards $5.7M in grants for infectious disease vaccine work. Story | Follow @EmilyMFierce

> PhIII judgment day looms for GlaxoSmithKline's heart drug darapladib. Story

> Global biopharma hub strategy doomed Novartis' outlying R&D facility. Article

Pharma News

@FiercePharma:  Best-read special report this weekend: Top 10 Patent Losses for 2014. Report | Follow @FiercePharma

@CarlyHFierce:  Rare-disease co. ViroPharma finally snatched up after lots of speculation - Shire gets it for $4.2B. Release | Follow @CarlyHFierce

> FDA slaps Aegerion for CEO's fast-and-loose interviews with CNBC. Story

> AstraZeneca to build £120 million U.K. plant. News

> Novartis hives off blood diagnostics for $1.7B in first slim-down sale. Article

CRO News

> Cel-Sci demands $50M from inVentiv over alleged trial fraud. More

> Quintiles paid $146.5M for Novella. Article

> Capsugel bets $20M on Bend's commercial manufacturing. Story

> AMRI steers clear of FDA warning letter after years of fixes. Piece

> Covance partners up for biologics safety testing. Story

Biotech IT News

> Scientists increasingly receptive to life science vendors on social media. News

> Open-access genomics database causes hand-wringing in U.K.. More

> Catalent creates web-based tool to ease drug delivery tech selection. Story

> BioDatomics pitches open-source, freemium bioinformatics package. Piece

> Advocacy groups crowdsourcing patient views on risk-benefit of drugs. News

Suggested Articles

Dexcom received a new European approval for its wearable continuous glucose monitor in pregnant women across Type 1, Type 2 and gestational diabetes.

Infectious disease blood tester Karius has raised $165 million led by SoftBank’s Vision Fund 2, the Japanese conglomerate’s sequel to its VC megafund.

BD will begin working with Babson Diagnostics to help bring its lab-quality device for collecting blood from capillaries into retail pharmacies.